Jaffer A. Ajani, MD, spoke about the recent approvals of nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with esophageal squamous cell carcinoma.
Approval Alert | Nivolumab-Based Regimens for Esophageal Squamous Cell Carcinoma
The FDA has granted approval to nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
2
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
3
Response Rates Show Promise in Phase 1 trial Involving ASCT in Metastatic PDAC
4
Case 2: Patient With High-Risk RRMM Relapsing After BCMA CAR T-Cell Therapy
5
